

# Stefania Croci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6521540/publications.pdf>

Version: 2024-02-01

94  
papers

2,309  
citations

218381

26  
h-index

233125

45  
g-index

98  
all docs

98  
docs citations

98  
times ranked

3101  
citing authors

#	ARTICLE	IF	CITATIONS
1	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes. <i>Biomedicines</i> , 2022, 10, 236.	1.4	13
2	Predictive factors of clinical outcomes in patients with COVID-19 treated with tocilizumab: A monocentric retrospective analysis. <i>PLoS ONE</i> , 2022, 17, e0262908.	1.1	2
3	Inflammatory burden and persistent CT lung abnormalities in COVID-19 patients. <i>Scientific Reports</i> , 2022, 12, 4270.	1.6	5
4	Mortality Prediction of COVID-19 Patients Using Radiomic and Neural Network Features Extracted from a Wide Chest X-ray Sample Size: A Robust Approach for Different Medical Imbalanced Scenarios. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 3903.	1.3	9
5	Follow-Up CT Patterns of Residual Lung Abnormalities in Severe COVID-19 Pneumonia Survivors: A Multicenter Retrospective Study. <i>Tomography</i> , 2022, 8, 1184-1195.	0.8	19
6	Rehabilitation Interventions for Post-Acute COVID-19 Syndrome: A Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5185.	1.2	95
7	Could different aqueous humor and plasma cytokine profiles help differentiate between ocular sarcoidosis and ocular tuberculosis?. <i>Inflammation Research</i> , 2022, 71, 949-961.	1.6	4
8	Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2021, 73, 402-408.	1.5	18
9	Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy. <i>Arthritis and Rheumatology</i> , 2021, 73, 48-52.	2.9	10
10	Vogt-Koyanagi-Harada patients show higher frequencies of circulating NKG2Dpos NK and NK T cells. <i>Clinical and Experimental Immunology</i> , 2021, 204, 41-48.	1.1	2
11	Preliminary Study of a 1,5-Benzodiazepine-Derivative Labelled with Indium-111 for CCK-2 Receptor Targeting. <i>Molecules</i> , 2021, 26, 918.	1.7	8
12	Efficacy of Rituximab Treatment in Vogt-Koyanagi-Harada Disease Poorly Controlled by Traditional Immunosuppressive Treatment. <i>Ocular Immunology and Inflammation</i> , 2021, , 1-6.	1.0	6
13	Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy. <i>Ocular Immunology and Inflammation</i> , 2021, , 1-9.	1.0	3
14	New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine?. <i>Lancet Rheumatology</i> , The, 2021, 3, e874-e885.	2.2	8
15	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12330.	1.8	16
16	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables. <i>Cells</i> , 2021, 10, 3166.	1.8	20
17	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations. <i>Cells</i> , 2021, 10, 3165.	1.8	9
18	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models). <i>International Journal of Molecular Sciences</i> , 2021, 22, 12297.	1.8	10

#	ARTICLE	IF	CITATIONS
19	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12314.	1.8	6
20	Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells. <i>Stem Cell Research and Therapy</i> , 2021, 12, 598.	2.4	21
21	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy. <i>Journal of Personalized Medicine</i> , 2021, 11, 1312.	1.1	6
22	Uveitis and Other Ocular Complications Following COVID-19 Vaccination. <i>Journal of Clinical Medicine</i> , 2021, 10, 5960.	1.0	92
23	Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 549-558.	1.6	29
24	Susceptibility and severity of COVID-19 in patients treated with bDMARDs and tsDMARDs: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 986.2-988.	0.5	49
25	Clinicopathological Bird's-Eye View of Left Atrial Myocardial Fibrosis in 121 Patients With Persistent Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007588.	2.1	9
26	Cytokine Profiling in Aqueous Humor Samples From Patients With Non-Infectious Uveitis Associated With Systemic Inflammatory Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 358.	2.2	36
27	Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 609204.	1.8	22
28	Significance of inflammation restricted to adventitial/periadventitial tissue on temporal artery biopsy. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1064-1072.	1.6	22
29	AB0039...ROLE OF MESENCHYMAL STEM CELLS ISOLATED FROM DENTAL PULP (DPSCS) IN IMMUNOREGULATION PROCESSES MEDIATED BY PROGRAMMED DEATH-LIGAND 1 (PD-L1). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1322.1-1322.	0.5	1
30	THU0314...RELAPSES AND LONG-TERM REMISSION IN LARGE VESSEL GIANT CELL ARTERITIS IN NORTHERN ITALY: CHARACTERISTICS AND PREDICTORS IN A LONG-TERM FOLLOW-UP STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 386.2-386.	0.5	0
31	Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1215-1222.	0.4	3
32	Copper-64 and fluorescein labeled anti-miRNA peptide nucleic acids for the detection of miRNA expression in living cells. <i>Nuclear Medicine and Biology</i> , 2019, 72-73, S44.	0.3	0
33	Large-Vessel Vasculitis. , 2019, , 609-618.		1
34	<sup>64</sup> Cu and fluorescein labeled anti-miRNA peptide nucleic acids for the detection of miRNA expression in living cells. <i>Scientific Reports</i> , 2019, 9, 3376.	1.6	13
35	Cancer Vaccines Co-Targeting HER2/Neu and IGF1R. <i>Cancers</i> , 2019, 11, 517.	1.7	7
36	Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis. <i>BMC Cancer</i> , 2019, 19, 126.	1.1	7

#	ARTICLE	IF	CITATIONS
37	The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis. <i>Journal of Autoimmunity</i> , 2019, 98, 113-121.	3.0	7
38	Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1074-1082.	1.6	40
39	Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. <i>Rheumatology</i> , 2018, 57, 1151-1155.	0.9	50
40	Increased expression of interleukin-22 in patients with giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 64-72.	0.9	20
41	Unmet Needs in the Pathogenesis and Treatment of Vasculitides. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 244-260.	2.9	21
42	Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet Disease. <i>Frontiers in Immunology</i> , 2018, 9, 2157.	2.2	13
43	Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients. <i>PLoS ONE</i> , 2018, 13, e0196350.	1.1	15
44	THU0457â€¦Interleukin-6 expression in inflamed and non-inflamed temporal arteries from patients with giant cell arteritis. , 2018, , .		0
45	Ectopic expression of CXCL13, BAFF, APRIL and LT-Î² is associated with artery tertiary lymphoid organs in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 235-243.	0.5	67
46	No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 235-240.	1.6	35
47	Uptake of Ga-curcumin derivatives in different cancer cell lines: Toward the development of new potential 68 Ga-labelled curcuminoids-based radiotracers for tumour imaging. <i>Journal of Inorganic Biochemistry</i> , 2017, 173, 113-119.	1.5	17
48	New insights into the pathogenesis of giant cell arteritis. <i>Autoimmunity Reviews</i> , 2017, 16, 675-683.	2.5	51
49	AB0563â€¦Rituximab in patients with takayasu arteritis: a seven patients experience. , 2017, , .		2
50	THU0035â€¦Cytokine profiling of aqueous humor in behçet's disease patients with active ocular involvement. , 2017, , .		0
51	AB0022â€¦Cytotoxic profile characterization of nk and nkt cells in patients with behçet disease. , 2017, , .		0
52	Affinity of nat/68Ga-Labelled Curcumin and Curcuminoid Complexes for Î²-Amyloid Plaques: Towards the Development of New Metal-Curcumin Based Radiotracers. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1480.	1.8	15
53	A possible correlation with the response in patients with metastatic lung caner: MicroRNA and Erlotinb. <i>Annals of Oncology</i> , 2016, 27, iv13.	0.6	0
54	SAT0352â€¦Analysis of Varicella-Zoster Virus in Temporal Artery Biopsies Positive and Negative for Giant Cell Arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 794.2-794.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Complex interplay between neutral and adaptive evolution shaped differential genomic background and disease susceptibility along the Italian peninsula. <i>Scientific Reports</i> , 2016, 6, 32513.	1.6	41
56	SAT0023...Artery Tertiary Lymphoid Organs Occur in Giant Cell Arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 672.1-672.	0.5	0
57	MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1527-1533.	0.5	37
58	EGFR-related miRNAs as potential biomarkers of response to Erlotinib in metastatic NSCLC patients. <i>Annals of Oncology</i> , 2015, 26, vi81.	0.6	0
59	THU0539...Clinical Presentation of Cryopyrin-Associated Periodic Syndrome (CAPS) in Carriers of the Q703K Mutation in the CIAS1/NLRP3 Gene: Genotype-Phenotype Characterization of a Family. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 395.2-395.	0.5	0
60	Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis. <i>Breast Cancer Research</i> , 2015, 17, 70.	2.2	11
61	Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. <i>Breast Cancer Research</i> , 2014, 16, R10.	2.2	27
62	Synthesis and Characterization of <sup>68</sup> Ga-Labeled Curcumin and Curcuminoid Complexes as Potential Radiotracers for Imaging of Cancer and Alzheimer's Disease. <i>Inorganic Chemistry</i> , 2014, 53, 4922-4933.	1.9	71
63	Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. <i>Oncotarget</i> , 2014, 5, 108-119.	0.8	12
64	Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus. <i>PLoS Pathogens</i> , 2013, 9, e1003155.	2.1	36
65	Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. <i>British Journal of Cancer</i> , 2012, 107, 1302-1309.	2.9	8
66	Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2 <sup>-/-</sup> ;Il2rg <sup>-/-</sup> Mice and Treatment with PI3K Inhibitor. <i>PLoS ONE</i> , 2012, 7, e39626.	1.1	78
67	Abstract 1403: Multiorgan metastasis of human HER-2+ breast cancer in immunodeficient mice. , 2012, , .		0
68	Abstract 2715: Treatment of disseminated HER-2 carcinomas with a HER-2-retargeted oncolytic herpes virus. , 2012, , .		0
69	HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines. <i>Vaccine</i> , 2011, 29, 4690-4697.	1.7	4
70	Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER2/neu oncogene-driven animal model system. <i>Proteomics</i> , 2010, 10, 3835-3853.	1.3	10
71	<i>In silico</i> Modeling and <i>In vivo</i> Efficacy of Cancer-Preventive Vaccinations. <i>Cancer Research</i> , 2010, 70, 7755-7763.	0.4	78
72	High metastatic efficiency of human sarcoma cells in Rag2 <sup>fl3c</sup> double knockout mice provides a powerful test system for antimetastatic targeted therapy. <i>European Journal of Cancer</i> , 2010, 46, 659-668.	1.3	26

#	ARTICLE	IF	CITATIONS
73	A Multi-DNA Preventive Vaccine for p53/Neu-Driven Cancer Syndrome. <i>Human Gene Therapy</i> , 2009, 20, 453-464.	1.4	11
74	Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9039-9044.	3.3	83
75	Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 754-761.	1.9	20
76	Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy. <i>Vaccine</i> , 2009, 27, 2065-2069.	1.7	1
77	Antimetastatic Activity of a Preventive Cancer Vaccine. <i>Cancer Research</i> , 2007, 67, 11037-11044.	0.4	47
78	Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. <i>International Journal of Cancer</i> , 2007, 121, 88-94.	2.3	5
79	Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. <i>Pathology and Oncology Research</i> , 2007, 13, 336-339.	0.9	8
80	Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells. <i>Oncology Reports</i> , 2007, 18, 451-6.	1.2	4
81	Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. <i>European Journal of Cancer</i> , 2006, 42, 680-687.	1.3	2
82	Antitumor Activity of the Insulin-Like Growth Factor-I Receptor Kinase Inhibitor NVP-AEW541 in Musculoskeletal Tumors. <i>Cancer Research</i> , 2005, 65, 3868-3876.	0.4	272
83	Expression of T cell receptor alpha gene (TCRA) in human rhabdomyosarcoma and other musculo-skeletal sarcomas. <i>Gene</i> , 2005, 353, 16-22.	1.0	2
84	Gene Expression Analysis of Immune-Mediated Arrest of Tumorigenesis in a Transgenic Mouse Model of HER-2/neu-Positive Basal-Like Mammary Carcinoma. <i>American Journal of Pathology</i> , 2005, 166, 1205-1216.	1.9	43
85	Toward the Definition of Immunosuppressive Regimens With Antitumor Activity. <i>Transplantation Proceedings</i> , 2005, 37, 2144-2147.	0.3	15
86	Inhibition of Connective Tissue Growth Factor (CTGF/CCN2) Expression Decreases the Survival and Myogenic Differentiation of Human Rhabdomyosarcoma Cells. <i>Cancer Research</i> , 2004, 64, 1730-1736.	0.4	83
87	Immunological Prevention of a Multigene Cancer Syndrome. <i>Cancer Research</i> , 2004, 64, 8428-8434.	0.4	19
88	Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine. <i>Cancer Research</i> , 2004, 64, 4001-4009.	0.4	87
89	Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN- $\gamma$ and B Cell Dependent. <i>Journal of Immunology</i> , 2004, 173, 2288-2296.	0.4	88
90	Apc10.1: AnApcMin/+ intestinal cell line with retention of heterozygosity. <i>International Journal of Cancer</i> , 2004, 109, 200-206.	2.3	17

#	ARTICLE	IF	CITATIONS
91	Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. International Journal of Cancer, 2003, 105, 384-389.	2.3	28
92	Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. Cancer Research, 2003, 63, 2728-32.	0.4	53
93	Identification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells. Gene, 2001, 274, 139-149.	1.0	46
94	Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells. Oncology Reports, 0, , .	1.2	2